Skip to content
Home/Companies/Biotech/Prilenia Therapeutics
Prilenia Therapeutics

Prilenia Therapeutics

Biotech·Netherlands·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Prilenia Therapeutics?

Prilenia Therapeutics is currently owned by SV Health Managers through SV7 Impact Medicine Fund (2019 vintage), since 2022.

Hand-verified · updated 2026-07-16

SV Health Managers
Investor
SV Health Managers
SV7 Impact Medicine Fund · 2019 · Life Sciences VC

Key facts

HQNetherlands
SectorBiotech
StatusActive
Websiteprilenia.com

More from SV7 Impact Medicine Fund

Other portfolio companies in the same fund.

AdvanCell
Active
BiotechAustralia· 2025
Draig Therapeutics
Draig Therapeutics
Active
BiotechUK· 2025
Rondo Therapeutics
Rondo Therapeutics
Active
BiotechUS· 2022
EyeBio
Exited 2024
BiotechUK· 2021
to
Mestag Therapeutics
Mestag Therapeutics
Active
BiotechUK· 2021
Quell Therapeutics
Quell Therapeutics
Active
BiotechUK· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Prilenia Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Prilenia Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Prilenia Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue